AUTHORS
Vladimir N Kolyadko, PhD, Ruth Anne Pumroy, PhD2, Vera Moiseenkova-Bell, PhD3, Sriram Krishnaswamy, PhD4
AFFILIATIONS
1 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Coagulation factor VIIIa (FVIIIa) is a cofactor protein that sequesters the proteinase, factor IXa (FIXa), on the membrane surface of procoagulant platelets to form the membrane-assembled intrinsic Xase complex. The intrinsic Xase is a crucial component of the coagulation system that regulates the hemostatic response, as deficiencies in its components cause hemophilia A and B. The emerging evidence on prothrombotic mutations in FVIIIa and FIXa, such as FVIII-Aurora (R571S mutation in the FVIII-A2 domain) and FIX-Padua (R170L mutation in the FIX catalytic domain), suggests an important role of the intrinsic Xase in the development of thrombosis. The molecular mechanism driving the assembly and function of the FVIIIa-FIXa-membrane complex remains elusive, as numerous conflicting models were previously proposed while experimental studies failed to provide high-resolution structural information. Here, we report a high-resolution cryo-electron microscopy (Cryo-EM) structure of the FVIIIa-FIXa (intrinsic Xase) complex on a procoagulant membrane. The intrinsic Xase was assembled with purified human full-length FVIII and FIXa (S195A), and small unilamellar vesicles containing 25% phosphatidylserine (Ptd-Ser), followed by treatment with thrombin and sample vitrification on Cryo-EM grids. Analysis by SDS-PAGE confirmed quantitative conversion of FVIII into FVIIIa in the Cryo-EM specimen. The FVIIIa-FIXa structure, determined at 2.8 Å resolution, reveals the molecular architecture of thrombin-activated FVIIIa and identifies an extended interaction interface with FIXa. Structural comparison of the FVIIIa-FIXa complex with the 2.6-Å Cryo-EM structure of the FVIII-FIXa complex, which was reported previously, provides new insights into the mechanistic basis of cofactor activity upon thrombin-catalyzed activation. Strikingly, the proteinase domain of FIXa is well resolved due to its stabilization in the complex with FVIIIa, while the FIXa proteinase domain in the complex with FVIII (without activation by thrombin) was motile and unable to form stable interactions. This difference is attributed to the stabilization of the acidic regions a1 and a3 in thrombin-activated FVIIIa. The a1 acidic region (373-Ser-Val-Ala-Lys-376) engages the so-called ‘allosteric’ 170-loop in FIXa and locks the 560-loop in FVIIIa, which contains the cleavage site by activated protein C (aPC) at Arg562. These changes suggest potential mechanisms for the allosteric regulation of FIXa and the protection of FVIIIa from degradation by aPC, respectively. Interestingly, the FVIIIa-FIXa interaction interface adjacent to the a1 acidic region contains an extended structural motif within the A2 domain of FVIIIa. This motif includes residue Arg571, the site of the prothrombotic FVIII-Aurora mutation, and binds to residue Arg170 of FIXa, which is the site of the prothrombotic FIX-Padua mutation. This highlights the importance of the interactions identified within the FVIIIa-FIXa complex in hemostasis and thrombosis. Additionally, the structure of the FVIIIa-FIXa complex further suggests a putative binding site for docking the substrate, factor X (FX), where an extended groove formed by the surfaces of FVIIIa and FIXa may accommodate the activation peptide of FX. Our work provides atomistic details in the intrinsic Xase function enabled by the high-resolution Cryo-EM structures. These structures bridge the existing functional data with the structural biology of FVIIIa and FIXa, allowing insights into the nature of cofactor activity and its role in regulating the intrinsic Xase.
DISCLOSURES
Vladimir N Kolyadko, PhD: No relevant conflicts of interest to declare.